share_log

Vertex Pharmaceuticals | SC TO-T: Third party tender offer statement

Vertex Pharmaceuticals | SC TO-T: Third party tender offer statement

福泰製藥 | SC TO-T:要約收購聲明
美股sec公告 ·  04/22 16:17
Moomoo AI 已提取核心訊息
Vertex Pharmaceuticals Incorporated (Vertex), through its wholly owned subsidiary Adams Merger Sub, Inc. (Purchaser), has announced the commencement of a tender offer to acquire all issued and outstanding shares of Alpine Immune Sciences, Inc. (Alpine). The offer is set at a purchase price of $65.00 per share, net to the seller in cash, without interest and subject to any applicable tax withholding. The tender offer is the initial step in Vertex's strategy to acquire the entire equity interest in Alpine, with plans to subsequently complete a merger, making Alpine a wholly owned subsidiary of Vertex. The offer is subject to certain conditions, including the minimum tender condition, regulatory approvals, and other customary conditions. Vertex expects to file the necessary notifications...Show More
Vertex Pharmaceuticals Incorporated (Vertex), through its wholly owned subsidiary Adams Merger Sub, Inc. (Purchaser), has announced the commencement of a tender offer to acquire all issued and outstanding shares of Alpine Immune Sciences, Inc. (Alpine). The offer is set at a purchase price of $65.00 per share, net to the seller in cash, without interest and subject to any applicable tax withholding. The tender offer is the initial step in Vertex's strategy to acquire the entire equity interest in Alpine, with plans to subsequently complete a merger, making Alpine a wholly owned subsidiary of Vertex. The offer is subject to certain conditions, including the minimum tender condition, regulatory approvals, and other customary conditions. Vertex expects to file the necessary notifications under the HSR Act and may need to comply with other antitrust laws. The board of directors of Alpine has unanimously recommended that shareholders accept the offer and tender their shares. The tender offer is not subject to any financing condition, as Vertex intends to fund the transaction with its existing cash resources. The offer is expected to expire at one minute past 11:59 P.M., Eastern Time, on May 17, 2024, unless extended or terminated earlier.
Vertex Pharmicals Incorporated(Vertex)通過其全資子公司Adams Merger Sub, Inc.(買方)宣佈開始收購阿爾卑斯免疫科學公司(Alpine)所有已發行和流通股份。該報價定爲每股65.00美元的收購價,向賣方淨收取現金,不含利息,並需繳納任何適用的預扣稅。此次要約是Vertex收購阿爾派全部股權戰略的第一步,並計劃隨後完成合並,使阿爾派成爲Vertex的全資子公司。該報價受某些條件的約束,包括最低投標條件、監管批准和其他慣例條件。Vertex預計將根據HSR法案提交必要的通知,並可能需要遵守其他反壟斷法。阿爾派董事會一致建議股東接受要約並投標股份。本次要約不受任何融資條件的約束,因爲Vertex打算用其現有現金資源爲交易提供資金。除非提前延長或終止,否則該優惠預計將在美國東部時間2024年5月17日晚上 11:59 之後的一分鐘到期。
Vertex Pharmicals Incorporated(Vertex)通過其全資子公司Adams Merger Sub, Inc.(買方)宣佈開始收購阿爾卑斯免疫科學公司(Alpine)所有已發行和流通股份。該報價定爲每股65.00美元的收購價,向賣方淨收取現金,不含利息,並需繳納任何適用的預扣稅。此次要約是Vertex收購阿爾派全部股權戰略的第一步,並計劃隨後完成合並,使阿爾派成爲Vertex的全資子公司。該報價受某些條件的約束,包括最低投標條件、監管批准和其他慣例條件。Vertex預計將根據HSR法案提交必要的通知,並可能需要遵守其他反壟斷法。阿爾派董事會一致建議股東接受要約並投標股份。本次要約不受任何融資條件的約束,因爲Vertex打算用其現有現金資源爲交易提供資金。除非提前延長或終止,否則該優惠預計將在美國東部時間2024年5月17日晚上 11:59 之後的一分鐘到期。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息